KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Equity (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Return on Equity for 17 consecutive years, with 0.58% as the latest value for Q1 2026.

  • For Q1 2026, Return on Equity rose 152.0% year-over-year to 0.58%; the TTM value through Mar 2026 reached 0.58%, up 152.0%, while the annual FY2025 figure was 0.73%, 289.0% down from the prior year.
  • Return on Equity hit 0.58% in Q1 2026 for Alnylam Pharmaceuticals, down from 0.62% in the prior quarter.
  • Across five years, Return on Equity topped out at 10.02% in Q4 2022 and bottomed at 22.69% in Q3 2024.
  • Average Return on Equity over 5 years is 1.81%, with a median of 0.58% recorded in 2026.
  • Year-over-year, Return on Equity soared 2359bps in 2023 and then plummeted -2447bps in 2024.
  • Alnylam Pharmaceuticals' Return on Equity stood at 10.02% in 2022, then plummeted by -77bps to 2.28% in 2023, then tumbled by -346bps to 5.59% in 2024, then soared by 111bps to 0.62% in 2025, then decreased by -7bps to 0.58% in 2026.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.58%, 0.62%, and 0.51% for Q1 2026, Q4 2025, and Q3 2025 respectively.